Involvement of Gadolinium Chelates in the Mechanism of Nephrogenic Systemic Fibrosis: An Update
Section snippets
Gadolinium
Gadolinium (atomic number Z = 64) belongs to the lanthanide series of elements. Its standard atomic weight is 157.25. Gadolinium was discovered in 1880 by the Swiss chemist Jean-Charles Galissard de Marignac, isolated by the French chemist Paul-Emile Lecoq de Boisbaudran in 1886, and named after the Finnish chemist Johann Gadolin, who, in 1794, analyzed the mineral gadolinite discovered at the Ytterby quarry, near Stockholm, by an amateur mineralogist.12 In addition to its medical imaging
Pharmacokinetics of gadolinium chelates
The pharmacokinetic behavior of GCs is of paramount importance for two reasons: (1) it strongly determines their imaging profile and efficiency and (2) it depends on certain physiologic functions, notably renal function, a feature that may play a major role in the mechanism of NSF.
GCs are highly hydrophilic molecules and share pharmacokinetic characteristics similar to those of water-soluble iodinated contrast agents. They can be regarded as tracers of the extracellular water, as shown by their
Physicochemical properties of gadolinium chelates
The effect of GCs on proton relaxation time and, consequently, their effect on the MR imaging signal depend on the large number of unpaired electrons of Gd3+ (n = 7). Because of its intrinsic toxicity, however, Gd3+ must be chelated by the administration of an appropriate ligand. Because Gd3+ is chelated, a thermodynamic equilibrium exists between the metal [M] (ie, Gd3+ in the present case), the ligand [L], and the chelate [ML]:Chemists involved in the field of GCs obviously try to
Free ligand
Because of their relatively low stability, pharmaceutic solutions of some GCs include a relatively large amount of free ligand or sodium salt of calcium complexes (see Table 1). These excipients are intended to ensure the absence of free Gd3+ cations in pharmaceutic solutions for the duration of their shelf lives.1, 2 According to the law of mass action (Equation 1), an excess in free ligand reduces the concentration of free Gd3+ and acts like a “gadolinium sponge.” The least stable agents
Hypotheses for the role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis
The low prevalence of the disease makes investigations on its mechanism quite difficult. Although no fully validated mechanism for NSF has been established to date, major advances have been made in the past 2 years.
In one case report,42 the clinical condition improved after renal transplantation and subsequently relapsed after renal function was lost and dialysis was restarted. This report suggests a link between renal function and clinical signs associated with NSF. The role of renal failure
Summary
There has occasionally been some confusion attributable to failure to discriminate between two complementary aspects (ie, thermodynamic and kinetic stability) to describe the stability of GCs.1, 2Fig. 2 illustrates release of free Gd3+ from theoretic GCs, which differ in terms of their thermodynamic and kinetic stabilities. The time frame of Fig. 2 depends on pathophysiologic conditions, such as renal insufficiency, and possible storage in a deep compartment, such as bone tissue, with slow and
Summary
GCs are not similar in terms of stability. High kinetic stability provided by the macrocyclic structure combined with high thermodynamic stability minimizes the amount of free gadolinium released in tissue parenchymas. Although no fully validated mechanism for NSF has been established to date, major advances have been made in the past 2 years thanks to in vitro and in vivo models.
References (84)
- et al.
Update on nephrogenic systemic fibrosis
Magn Reson Imaging Clin N Am
(2008) - et al.
Gadolinium limits myocardial infarction in the rat: dose-response, temporal relations and mechanisms
J Mol Cell Cardiol
(2008) - et al.
Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers
Acad Radiol
(1999) - et al.
Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis
Acad Radiol
(1998) - et al.
Reaction of gadolinium chelates with endogenously available ions
Magn Reson Imaging
(1991) - et al.
Dissociation of gadolinium chelates in mice: relationship to chemical characteristics
Magn Reson Imaging
(1992) - et al.
Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-aza-phosphinic and carboxylic acids
Magn Reson Imaging
(1993) - et al.
The relationship between thermodynamics and the toxicity of gadolinium complexes
Magn Reson Imaging
(1990) - et al.
Nephrogenic fibrosing dermopathy with recurrence after allograft failure
J Am Acad Dermatol
(2007) Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium
Adv Dermatol
(2007)
Extracellular Gd-CA: differences in prevalence of NSF
Eur J Radiol
Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement
J Am Acad Dermatol
Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate
Kidney Int
Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature
Semin Arthritis Rheum
Clinical and histological findings in nephrogenic systemic fibrosis
Eur J Radiol
Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis
Eur J Radiol
Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis
J Am Acad Dermatol
Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review
Toxicology
MMP-1: the elder in the family
Int J Biochem Cell Biol
Forefronts in nephrology: summary of the newer aspects of renal cell injury
Kidney Int
Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review
Fundam Clin Pharmacol
Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review
Biometals
Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents
Contrast Media Mol Imaging
Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications
Chem Rev
Allergic-like breakthrough reactions to gadolinium contrast agents after corticosteroid and antihistamine reactions
Am J Roentgenol
Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency
Radiology
Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?
Nephrol Dial Transplant
Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging
J Am Soc Nephrol
Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis
Nephrol Dial Transplant
Thorotrast toxicity: the safety of gadolinium compounds
Neth J Med
Gadolinium: named after Finland's most famous chemist
Br J Radiol
Toxicological and cytophysiological aspects of lanthanides action
Acta Biochim Pol
Basic experimental studies and clinical aspects of gadolinium salts and chelates
Cardiovasc Drug Rev
Intralysosomal accumulation of gadolinium and lysosomal damage during selective depression of liver macrophages in vivo
Bull Exp Biol Med
Gadolinium chloride toxicity in the rat
Toxicol Pathol
The occurrence and metabolism of lanthanides
Using gadolinium to identify stretch-activated channels
Am J Physiol
Magnetic resonance contrast agents: from the bench to the patient
Curr Pharm Des
Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: safety, pharmacokinetics, and MR imaging
Radiology
Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis
J Magn Reson Imaging
A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent
Invest Radiol
Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment
Invest Radiol
Cited by (79)
In vivo monitoring platform of transplanted human stem cells using magnetic resonance imaging
2021, Biosensors and BioelectronicsCoordination polymers nanoparticles for bioimaging
2021, Coordination Chemistry ReviewsCitation Excerpt :To address this issue, other active-MRI metals have been explored. Manganese, which has relaxivity values comparable to Gd, is one of the most used alternatives for the formation of NPs [105]. For instance, Taylor et al. described the controlled synthesis of CPNs, using Mn2+ and terephthalic (BTC)/trimesic (BTC) acids as coordination ligands, coated with a silica shell [94].
Albumin nanocomposites with MnO<inf>2</inf>/Gd<inf>2</inf>O<inf>3</inf> motifs for precise MR imaging of acute myocardial infarction in rabbit models
2020, BiomaterialsCitation Excerpt :Moreover, the albumin conjugated Gd-DTPA (albumin-Gd-DTPA) was also tested for MR imaging of MI, but it requires intravenous (i.v.) injection of high dose (i.e., 160 mL/kg) and followed by reperfusion for 60 min [15,16]. The rapid clearance from the blood circulation [17], potential renal risks [18] and poor selectivity of gadolinium chelates-based CAs to MI regions [14], encouraged further development of CAs (e.g., nanoparticle-CAs) to improve the diagnostic accuracy of MI. Nanoparticle-CAs have attracted much attention for MRI, for instance, the T1-weighted ones (e.g., Gd-, Mn-based nanoparticle-CAs) could specifically boost positive contrast enhancement [19–23], while the T2-weighted ones (e.g., iron oxide nanoparticles) could selectively give negative contrast enhancement [24].
External field-assisted laser ablation in liquid: An efficient strategy for nanocrystal synthesis and nanostructure assembly
2017, Progress in Materials ScienceCarbon Dots for Multiuse Platform: Intracellular pH Sensing and Complementary Intensified T1-T2 Dual Imaging Contrast Nanoprobes
2024, ACS Biomaterials Science and Engineering